Panhematin Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The panhematin market size has grown rapidly in recent years. It will grow from $2.42 million in 2025 to $2.71 million in 2026 at a compound annual growth rate (CAGR) of 12.1%. The growth in the historic period can be attributed to limited treatment options for porphyria, orphan drug approvals, hospital emergency usage, specialist metabolic disorder centers, patient advocacy efforts.

The panhematin market size is expected to see rapid growth in the next few years. It will grow to $4.24 million in 2030 at a compound annual growth rate (CAGR) of 11.8%. The growth in the forecast period can be attributed to improved rare disease diagnosis, expansion of acute porphyria awareness, increased access to orphan drugs, supportive reimbursement policies, growth of specialty care centers. Major trends in the forecast period include rising use in acute porphyria management, growth of orphan drug treatments, increased focus on rare metabolic disorders, expansion of hospital based emergency therapies, improved diagnostic awareness of porphyria.

The increasing diagnosis of genetic disorders is expected to drive the growth of the Panhematin market in the coming years. Genetic disorders are medical conditions caused by abnormalities in an individual’s genetic material and often require specialized treatments. The rise in diagnoses is driven by advancements in genetic testing and growing awareness, which enable early detection and timely intervention. Panhematin, used in the treatment of acute porphyrias, provides a synthetic form of heme that helps restore the body’s ability to regulate porphyrin and heme production. This alleviates symptoms such as severe abdominal pain, nausea, and neurological complications that result from the accumulation of toxic porphyrins due to enzyme deficiencies in the heme biosynthesis pathway. For example, in April 2023, the New England Journal of Medicine, a US-based medical journal, reported that approximately 5,500 individuals with severe developmental disorders have now been identified with the genetic cause of their condition. Therefore, the rising diagnosis of genetic disorders is driving the Panhematin market.

The increasing prevalence of blood disorders is also expected to support the growth of the Panhematin market. Blood disorders affect the production, function, or structure of blood cells, leading to conditions such as anemia, clotting problems, or immune dysfunction. The rise in blood disorders is primarily due to genetic predispositions, lifestyle changes, environmental factors, and aging populations. Panhematin, a form of heme arginate, helps patients with blood disorders, particularly acute intermittent porphyria and related conditions, by supplying a synthesized heme molecule that bypasses defective enzymes in the heme production pathway. This reduces the toxic buildup of porphyrins and alleviates symptoms such as pain, weakness, and neurological disturbances. For instance, in May 2024, the National Health Service (NHS) England, a UK-based government-funded healthcare system, reported that approximately 17,000 people in England are living with sickle cell disease, an inherited blood disorder, with around 250 new cases diagnosed annually. Consequently, the rising incidence of blood disorders is driving the Panhematin market.

Rising healthcare expenditure is further expected to propel the growth of the Panhematin market. Healthcare expenditure refers to the financial resources allocated to medical services, including diagnostics, treatments, and therapies, by governments, private entities, and individuals. The growth in spending is driven by an aging population, prevalence of chronic diseases, advances in medical technology, and increased demand for quality healthcare services. For Panhematin, healthcare expenditure covers the cost of treating acute porphyria attacks, including the drug itself, hospitalization, and associated care, ensuring effective management of this rare genetic disorder. For example, in May 2024, the Office for National Statistics, a UK-based government agency, reported that total healthcare expenditure increased by 5.6% in nominal terms from 2022 to 2023, compared to 0.9% growth in 2022. Additionally, long-term health and social care expenditure rose by 2.8% in real terms in 2022. Therefore, rising healthcare expenditure is driving the Panhematin market.

Major companies operating in the panhematin market are Horizon Therapeutics plc.

North America was the largest region in the panhematin market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the panhematin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the panhematin market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have affected the panhematin market by increasing costs associated with imported hemin raw materials, sterile formulation processes, and hospital supply logistics. These impacts are significant due to low volume and high value treatment profiles. Regions dependent on cross-border pharmaceutical sourcing such as north america and europe face supply sensitivity. However, tariffs are encouraging regional production and secure supply agreements. This supports long-term availability for critical rare disease therapies.

The panhematin market research report is one of a series of new reports that provides panhematin market statistics, including panhematin industry global market size, regional shares, competitors with a panhematin market share, detailed panhematin market segments, market trends and opportunities, and any further data you may need to thrive in the panhematin industry. This panhematin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Panhematin is a hemin-based medication primarily used to treat acute porphyrias, a group of rare metabolic disorders that affect heme production. It works by restoring heme levels, which helps suppress the buildup of porphyrin precursors that trigger symptoms.

The main forms of Panhematin are 350 mg and 313 mg. The 350 mg dose is used specifically for managing acute porphyria episodes. Its primary indication is acute porphyria, and it is administered in settings such as hospitals and pharmacies.

The panhematin market consists of sales of intravenous (IV) formulations used to treat acute intermittent porphyria (AIP) and related heme synthesis disorders. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.